Literature DB >> 7574535

Drug interactions with zidovudine phosphorylation in vitro.

P G Hoggard1, G J Veal, M J Wild, M G Barry, D J Back.   

Abstract

We have investigated the effect of a range of drugs (some commonly coadministered with zidovudine [ZDV] to human immunodeficiency virus-positive patients) on intracellular phosphorylation of ZDV by stimulated peripheral blood mononuclear cells, Molt 4 cells, and U937 cells in vitro. Of the drugs tested (azoles, antiviral agents, antibiotics, and anticancer agents), only doxorubicin and ribavirin caused inhibition of anabolite formation as measured by high-performance liquid chromatography. This in vitro approach may provide important leads to potential interactions at the phosphorylation level in patients with human immunodeficiency virus disease. It is reassuring that so many commonly administered drugs do not alter ZDV phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574535      PMCID: PMC162746          DOI: 10.1128/AAC.39.6.1376

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses.

Authors:  P Kremers; J Duvivier; C Heusghem
Journal:  J Clin Pharmacol       Date:  1974 Feb-Mar       Impact factor: 3.126

2.  Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases.

Authors:  Y C Cheng; G Dutschman; J J Fox; K A Watanabe; H Machida
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

3.  Human pharmacokinetics of the antiviral drug DHPG.

Authors:  C Fletcher; R Sawchuk; B Chinnock; P de Miranda; H H Balfour
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

4.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors:  O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

6.  Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals.

Authors:  R J Whitley; M R Blum; N Barton; P de Miranda
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

7.  Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects.

Authors:  K W Hall; C H Nightingale; M Gibaldi; E Nelson; T R Bates; A R DiSanto
Journal:  J Clin Pharmacol       Date:  1982-07       Impact factor: 3.126

8.  Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells.

Authors:  M Qian; G Chandrasena; R J Ho; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.

Authors:  A K Field; M E Davies; C DeWitt; H C Perry; R Liou; J Germershausen; J D Karkas; W T Ashton; D B Johnston; R L Tolman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

10.  Ribavirin antagonizes the effect of azidothymidine on HIV replication.

Authors:  M W Vogt; K L Hartshorn; P A Furman; T C Chou; J A Fyfe; L A Coleman; C Crumpacker; R T Schooley; M S Hirsch
Journal:  Science       Date:  1987-03-13       Impact factor: 47.728

View more
  8 in total

1.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.

Authors:  P G Hoggard; V Manion; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

3.  Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.

Authors:  M Rodriguez-Torres; F J Torriani; V Soriano; M J Borucki; E Lissen; M Sulkowski; D Dieterich; K Wang; J-M Gries; P G Hoggard; D Back
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Authors:  P G Hoggard; S Kewn; M G Barry; S H Khoo; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Yongbiao Guan; Ting-Chao Chou; Katsunori Takashima; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

Authors:  R M Hoetelmans; D M Burger; P L Meenhorst; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

7.  Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid.

Authors:  C B Trapnell; R W Klecker; C Jamis-Dow; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 8.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.